Shares in Grifols traded 6% higher at 8.63 euros in European afternoon trading, paring back gains of as much as 15% earlier in the session, after both Grifols and Brookfield issued their statements.

But Grifols's board and Brookfield said they weren't in takeover talks. "Brookfield is not, and has not been, in discussions with the company's board of directors with respect to a potential ...

Spanish pharma company Grifols’ shares up on Brookfield talk Stock Markets Published 04/02/2025, 03:06 AM Updated 04/02/2025, 10:01 AM ...

According to El Confidencial, Brookfield has re-engaged with the Grifols family, the company’s largest shareholder, and is contemplating a potential offer that could value Grifols at 7 billion euros ...

Canadian investment fund Brookfield (NYSE:BAM) resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols (NASDAQ:GRFS), El Confidencial reported on Wednesday, citing ...

Grifols' board also said on Wednesday it was not discussing a possible bid by Brookfield. The Grifols family, which is represented on the board, declined to comment. ($1 = 0.9246 euros) ...

The blue-chip IBEX35 Index was down 0.1 per cent. In its stock market filing, Brookfield said it maintained “a general dialogue with Grifols’ reference shareholders” without being more specific.

Earlier this month, Grifols reported a 12% increase in revenue to €1.79 billion in the 2024 third quarter, led by its biopharma division, with operating profit up almost 27% to €462 million.

Grifols SA has included a term in its €1.3 billion ($1.4 billion) private debt placement that would allow Brookfield Asset Management Ltd. to refinance the deal early — a sign the Spanish drugmaker is ...

Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion).